Roivant Sciences LTD Form 4 insider transactions

Rakhi Kumar, Chief Accounting Officer of Roivant Sciences, exercised stock options and sold shares on February 13, 2025, according to a recent SEC filing.

Roivant Sciences' President & COO, Eric Venker, executed stock options and sold a portion of the acquired shares, as detailed in a recent SEC filing.

Roivant Sciences CFO Richard Pulik sold 1,896 common shares to cover tax obligations related to the vesting of restricted stock units.

Director Melissa B. Epperly of Roivant Sciences Ltd. reports the acquisition of 1,672 common shares and the disposal of 180 common shares to cover tax obligations.

Director James C. Momtazee of Roivant Sciences Ltd. reports the acquisition of 1,248 common shares and the disposal of 306 shares for tax obligations.

Director Ilan Oren of Roivant Sciences Ltd. reports the acquisition and disposal of common shares related to a director compensation plan.

Director Vivek Ramaswamy transferred 13,357,857 common shares of Roivant Sciences Ltd. to a spouse for estate planning purposes on January 23, 2025.

Rakhi Kumar, Chief Accounting Officer of Roivant Sciences, sold 1,057 common shares to cover tax obligations related to the vesting of restricted stock units.

Roivant Sciences' President and COO, Eric Venker, engaged in multiple stock transactions, including the vesting of restricted stock units and the exercise and sale of stock options, as part of a pre-arranged trading plan.

Roivant Sciences CEO Matthew Gline sold 11,623 common shares to cover tax obligations related to the vesting of restricted stock units.

Roivant Sciences Ltd., a significant shareholder in Immunovant, Inc., reports acquiring 16,845,010 shares of common stock at $20 per share on January 13, 2025, increasing its direct holdings to 96,650,341 shares.

Roivant Sciences CFO Richard Pulik sold 1,896 common shares to cover tax obligations related to the vesting of restricted stock units.

Roivant Sciences' President and COO, Eric Venker, exercised stock options and sold a portion of the acquired shares in late December 2024.

Roivant Sciences' President and Chief Investment Officer, Mayukh Sukhatme, executed multiple transactions involving the exercise of stock options and the sale of common shares over a four-day period.

Roivant Sciences CFO Richard Pulik sold 2,129 common shares to cover tax obligations related to the vesting of restricted stock units.

Rakhi Kumar, Chief Accounting Officer of Roivant Sciences, sold 3,087 common shares to cover tax obligations related to vested Restricted Stock Units (RSUs).

Roivant Sciences' President and COO, Eric Venker, engaged in multiple stock transactions including the vesting of RSUs, option exercises, and share sales on December 20, 2024.

Roivant Sciences CEO Matthew Gline sold 10,945 common shares to cover tax obligations related to the vesting of restricted stock units.

Mayukh Sukhatme, a Roivant Sciences executive, exercised stock options and sold a portion of his holdings on December 18, 2024.

Mayukh Sukhatme, President and Chief Investment Officer of Roivant Sciences, transferred 3,651,985 common shares for estate planning purposes.

Roivant Sciences CFO Richard Pulik disposed of 2,341 common shares to cover tax obligations related to vested RSUs.

Rakhi Kumar, Chief Accounting Officer of Roivant Sciences, sold 958 common shares to cover tax obligations related to vested RSUs.

Roivant Sciences CEO Matthew Gline sold 10,945 common shares to cover tax obligations related to the vesting of restricted stock units.

Roivant Sciences' President and COO, Eric Venker, exercised stock options, sold shares, and had shares withheld for tax obligations on November 20, 2024.

Richard Pulik, CFO of Roivant Sciences, disposed of 2,341 common shares to cover tax withholding obligations related to vested RSUs.

Director James C. Momtazee reports acquiring 1,231 common shares of Roivant Sciences Ltd. through a non-employee director compensation plan.

Director Melissa Epperly received 1,613 common shares of Roivant Sciences Ltd. as part of the company's Non-Employee Director Compensation Plan.

Director Ilan Oren reports acquiring 2,303 common shares of Roivant Sciences Ltd. through an award under the company's Non-Employee Director Compensation Plan.

Eric Venker, President & COO of Roivant Sciences, reports the acquisition and disposal of common shares and stock options.

Rakhi Kumar, Chief Accounting Officer of Roivant Sciences Ltd., reports the disposal of 956 common shares to cover tax obligations related to vested RSUs on October 20, 2024.